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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S489results indicate that the amyloid structures could potentially be used for
cartilage tissue engineering. The next steps include culturing chon-
drocytes with amyloid structures in a 3D hydrogel to provide a more
realistic surrounding to the cells and to preserve the chondrocyte
phenotype. Microscopy image of bovine chondrocytes (dark) in culture
with a-synuclein amyloid aggregates (transparent). The dark color of
the cells is caused by formazan crystals as a result of the MTT assay.
Scale bar represent 100 mm.
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Purpose: Our laboratory has adopted a chondrocyte-seeded collagen
sponge system for tissue-engineering of cartilage. We have recently
developed an efﬁcient procedure to amplify human chondrocytes in
culture with a cocktail of ﬁbroblast growth factor (FGF)-2 and insulin
(FI). This cocktail allows the ampliﬁed chondrocytes to build a cartilage
matrix in collagen scaffolds, in the presence of bone morphogenetic
protein (BMP)-2, insulin and triiodothyronine (BIT). Here, we inves-
tigated if the dog model can be used to test in vivo implantation of the
cartilage construct for resurfacing articular cartilage defects.
Methods: Osteochondral blocks were harvested from cadavers of
skeletally mature male beagle dogs. Lateral and medial femoral con-
dyles (weight bearing sites) and femoral trochlea (non weight bearing
site) were processed for immunohistochemical analyses. Several pri-
mary antibodies against collagen proteins were screened on tissue
sections, with particular attention given to their ability to speciﬁcally
recognize collagen molecules characteristic of cartilage (type II colla-
gen) or bone and ﬁbrotic tissues (type I collagen). For in vitro recon-
struction of tissue-engineered cartilage, isolated canine articular
chondrocytes were ampliﬁed with the FI cocktail then cultured for 3
weeks in collagen sponges with the BIT cocktail. The neo-synthesized
matrix was evaluated by Western-blotting and immunohistochemical
analyses.
Results: We selected commercially available human anti-type I and
anti-type II collagen antibodies (Novotec, France) that were able to
discriminate canine type I and type II collagen proteins, as judged by the
mutually exclusive immunohistological stainings of cartilage and bone
by the two antibodies. In addition we developed an original antibody
capable of detecting the IIB form of type II collagen, the unique carti-
lage-speciﬁc isoform of type II collagen. Regarding cartilage recon-
struction in the collagen scaffolds, canine chondrocytes were able to
synthesize large amount of cartilage-characteristic proteins (such as
type II and type IX collagens). Interestingly, our Western-blotting
analysis also indicated that most of the type II collagen produced was
type IIB. Very importantly, our immunohistochemical and Western-
blotting analyses revealed extremely low amounts of type I collagen
production.
Conclusions: The combination of the FI and BIT cocktails during
expansion and culture of adult canine chondrocytes in collagen scaf-
folds led to the formation of cartilage whose biochemical composition
closely resembles to native cartilage. Thus, canine and human chon-
drocytes respond similarly to the FI and BIT cocktails. We have also
shown here that the biochemical quality of the cartilage matrix
reconstructed by canine chondrocytes can be evaluated by the use of
speciﬁc antibodies. The next step will be to test the functional proper-
ties of the tissue-engineered cartilage after implantation in the dog
knee joint. We have selected the adult canine animal model because it
offers several advantages: its clinical relevancewith respect to anatomy,
function, and clinical disorders in veterinary medicine (similar to
humans, dogs lack signiﬁcant intrinsic ability to heal cartilage defects
and suffer from cartilage problems such as osteochondritis dissecansand OA); the ability to perform surgical treatments such as arthroplasty,
chondrocyte transplantation and osteochondral grafting, as well as
postoperative management protocols. These features are important for
future validation and comparison of tissue engineering to the accepted
clinical treatments.
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Purpose: Articular cartilage, is of great importance for physiological
mobility. The structure and the function of this tissue, which is char-
acterized by a poor self-repair capacity, are frequently disrupted or
damaged upon physical trauma or in degenerative osteoarthritis (OA).
Given that musculoskeletal disorders are the leading cause of poor
performance or early retirement of sports and race horses, treating
horses for these disorders is relevant. The proposed therapeutic
approach, which was ﬁrst developed for human, has the potential of
being considered as a pre-clinical step for human medicine because the
horse is recognized as an excellent model for the study of articular
cartilage disorders in humans.
This study aims to improve the Autologous Chondrocytes Implantation
(ACI) technique by using Mesenchymal Stem cells (MSCs) from bone
marrow (easy to collect in horse) as the cell source. Thus, MSCs were,
ﬁrst, characterized before being cultured with chondrogenic conditions
in order to ﬁnd the combination that best enhances and stabilizes the
characteristics of the chondrocyte phenotype, in order to perform
clinical trials in horse.
Methods: MSCs from equine bone marrow were isolated and
expanded in monolayer cultures until 4 passages. These cells were
characterized by analyzing their proliferative potential, their pluri-
potency (with microenvironmental stimuli) and their capacity to
express MSCs speciﬁc phenotypic markers deﬁning the MSCs (ﬂow
cytometry). In parallel, MSCs differentiation in chondrocytes was
accomplished via a combinatory approach based on the association of
3D-culture in type I collagen sponges, low oxygen tension with
chondrogenic factors (BMP-2, TGF-b1) and RNA interference (siRNA to
down-regulate type I collagen and HtrA1 protein expression). Finally,
an extensive analysis at gene and protein levels corresponding to
differentiated, dedifferentiated and hypertrophic chondrocyte pheno-
types was performed.
Results: Our results show a very high proliferation potential of MSCs
isolated from equine bone marrow. Furthermore, the isolated cells
satisfy the various criteria of stem cells deﬁnition (pluripotency,
expression of surface markers). In addition, siRNAs targeting equine
Col1a1 and Htra1 have been functionally validated. Finally, we show
that the BMP-2 and TGF-b1 combination strongly induces the differ-
entiation of MSCs in chondrocytes. Thus, the combined use of speciﬁc
culture conditions deﬁned within the laboratory, with speciﬁc growth
factors and siRNAs association leads to the in vitro synthesis of a hyaline
type neo-cartilage by chondrocytes which present an optimal pheno-
typic index, comparable to the one established with induction of spe-
ciﬁc differentiation of human MSCs in chondrocytes, and close to the
one of differentiated/healthy chondrocytes.
Conclusions: These data represent a ﬁrst step in the development of
equine clinical trials, which are planed - to better understand the
reaction of cartilage tissue after a few weeks of intra-articular implan-
tation and - to make the proof of concept in a large animal model.
This approach will allow us to explore the criteria necessary to begin
to consider the development of cell therapy for cartilage repair in
humans.
